WO2009107850A3 - Fused heterocyclic derivative and use thereof - Google Patents

Fused heterocyclic derivative and use thereof Download PDF

Info

Publication number
WO2009107850A3
WO2009107850A3 PCT/JP2009/054007 JP2009054007W WO2009107850A3 WO 2009107850 A3 WO2009107850 A3 WO 2009107850A3 JP 2009054007 W JP2009054007 W JP 2009054007W WO 2009107850 A3 WO2009107850 A3 WO 2009107850A3
Authority
WO
WIPO (PCT)
Prior art keywords
optionally
substituent
ring
fused heterocyclic
heterocyclic derivative
Prior art date
Application number
PCT/JP2009/054007
Other languages
French (fr)
Other versions
WO2009107850A2 (en
Inventor
Nobuhiro Fujii
Yuya Oguro
Satoshi Sasaki
Shigeru Kondo
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP09714922.3A priority Critical patent/EP2247588B1/en
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Priority to ES09714922.3T priority patent/ES2586252T3/en
Priority to MX2010009372A priority patent/MX2010009372A/en
Priority to UAA201011405A priority patent/UA101021C2/en
Priority to AU2009217982A priority patent/AU2009217982B2/en
Priority to JP2010533355A priority patent/JP4719317B2/en
Priority to BRPI0908417-7A priority patent/BRPI0908417B1/en
Priority to CN2009801148111A priority patent/CN102015705B/en
Priority to US12/919,413 priority patent/US8399449B2/en
Priority to NZ587719A priority patent/NZ587719A/en
Priority to CA2716773A priority patent/CA2716773C/en
Priority to EA201070994A priority patent/EA020144B1/en
Publication of WO2009107850A2 publication Critical patent/WO2009107850A2/en
Publication of WO2009107850A3 publication Critical patent/WO2009107850A3/en
Priority to TNP2010000381A priority patent/TN2010000381A1/en
Priority to IL207735A priority patent/IL207735A/en
Priority to ZA2010/06063A priority patent/ZA201006063B/en
Priority to MA33195A priority patent/MA32164B1/en
Priority to HK11104328.2A priority patent/HK1150274A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

The present invention provides a compound having a superior Smo inhibitory activity and lower toxicity, which is sufficiently satisfactory as a pharmaceutical product.The present invention provides a compound represented by the formula (I) wherein ring A is 5- to 7-membered ring optionally having substituent(s), where substituents are optionally bonded to each other to form a ring; X is O, S or NR1 (R1 is a hydrogen atom or a hydrocarbon group optionally having substituent(s)); R2 is carbamoyl optionally having substituent(s); and R3 is hydroxy optionally having substituent(s), or a salt thereof.
PCT/JP2009/054007 2008-02-26 2009-02-25 Fused heterocyclic derivative and use thereof WO2009107850A2 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
CN2009801148111A CN102015705B (en) 2008-02-26 2009-02-25 Fused heterocyclic derivative and use thereof
ES09714922.3T ES2586252T3 (en) 2008-02-26 2009-02-25 Condensed heterocyclic derivative and use thereof
MX2010009372A MX2010009372A (en) 2008-02-26 2009-02-25 Fused heterocyclic derivative and use thereof.
UAA201011405A UA101021C2 (en) 2008-02-26 2009-02-25 Fused heterocyclic derivative and use thereof
AU2009217982A AU2009217982B2 (en) 2008-02-26 2009-02-25 Fused heterocyclic derivative and use thereof
JP2010533355A JP4719317B2 (en) 2008-02-26 2009-02-25 Fused heterocyclic derivatives and uses thereof
NZ587719A NZ587719A (en) 2008-02-26 2009-02-25 Fused heterocyclic derivative and use thereof
US12/919,413 US8399449B2 (en) 2008-02-26 2009-02-25 Fused heterocyclic derivative and use thereof
BRPI0908417-7A BRPI0908417B1 (en) 2008-02-26 2009-02-25 COMPOUND AND USE OF COMPOUND
EP09714922.3A EP2247588B1 (en) 2008-02-26 2009-02-25 Fused heterocyclic derivative and use thereof
CA2716773A CA2716773C (en) 2008-02-26 2009-02-25 Fused heterocyclic derivative and use thereof
EA201070994A EA020144B1 (en) 2008-02-26 2009-02-25 Fused pyridine derivatives and use thereof
TNP2010000381A TN2010000381A1 (en) 2009-02-25 2010-08-19 Fused heterocyclic derivative and use thereof
IL207735A IL207735A (en) 2008-02-26 2010-08-22 Fused heterocyclic derivative and use thereof
ZA2010/06063A ZA201006063B (en) 2008-02-26 2010-08-25 Fused heterocyclic derivative and use thereof
MA33195A MA32164B1 (en) 2008-02-26 2010-09-21 Heterocyclic derivative fuses and its use
HK11104328.2A HK1150274A1 (en) 2008-02-26 2011-04-29 Fused heterocyclic derivative and use thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2008-045134 2008-02-26
JP2008045134 2008-02-26
JP2008256755 2008-10-01
JP2008-256755 2008-10-01

Publications (2)

Publication Number Publication Date
WO2009107850A2 WO2009107850A2 (en) 2009-09-03
WO2009107850A3 true WO2009107850A3 (en) 2010-01-28

Family

ID=40905094

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2009/054007 WO2009107850A2 (en) 2008-02-26 2009-02-25 Fused heterocyclic derivative and use thereof

Country Status (28)

Country Link
US (2) US8217176B2 (en)
EP (1) EP2247588B1 (en)
JP (2) JP4719317B2 (en)
KR (1) KR101569949B1 (en)
CN (1) CN102015705B (en)
AR (1) AR070479A1 (en)
AU (1) AU2009217982B2 (en)
BR (1) BRPI0908417B1 (en)
CA (1) CA2716773C (en)
CL (1) CL2009000429A1 (en)
CO (1) CO6321277A2 (en)
CR (1) CR11661A (en)
DO (1) DOP2010000260A (en)
EA (1) EA020144B1 (en)
EC (1) ECSP10010496A (en)
ES (1) ES2586252T3 (en)
GE (1) GEP20125664B (en)
HK (1) HK1150274A1 (en)
IL (1) IL207735A (en)
JO (1) JO3259B1 (en)
MA (1) MA32164B1 (en)
MX (1) MX2010009372A (en)
MY (1) MY150379A (en)
NZ (1) NZ587719A (en)
PE (1) PE20091556A1 (en)
TW (1) TWI480282B (en)
WO (1) WO2009107850A2 (en)
ZA (1) ZA201006063B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113429422B (en) * 2021-07-26 2022-05-10 中国人民解放军军事科学院军事医学研究院 Thienoquinolone compound and preparation method and application thereof

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102015705B (en) * 2008-02-26 2013-11-13 武田药品工业株式会社 Fused heterocyclic derivative and use thereof
SI2459176T1 (en) 2009-07-31 2018-01-31 Gruenenthal Gmbh Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
WO2011013752A1 (en) * 2009-07-31 2011-02-03 塩野義製薬株式会社 Pharmaceutical composition containing fused hetero-ring derivative
JP5722781B2 (en) 2009-08-26 2015-05-27 武田薬品工業株式会社 Fused heterocyclic derivatives and uses thereof
WO2011024871A1 (en) * 2009-08-26 2011-03-03 武田薬品工業株式会社 Fused heterocyclic ring derivative and use thereof
SG178504A1 (en) * 2009-08-26 2012-04-27 Takeda Pharmaceutical Fused heterocyclic ring derivative and use thereof
JP5739334B2 (en) 2009-08-26 2015-06-24 武田薬品工業株式会社 Fused heterocyclic derivatives and uses thereof
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
WO2012154731A1 (en) * 2011-05-08 2012-11-15 Vanderbilt University Substituted 1h-pyrrolo[3,2-c]quinolin-4(5h)-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
US8975398B2 (en) 2012-05-11 2015-03-10 Abbvie Inc. NAMPT inhibitors
WO2015084958A1 (en) * 2013-12-03 2015-06-11 Lee Allen J Rationale-based design of a targeted therapy for cancer
WO2015140964A1 (en) 2014-03-19 2015-09-24 株式会社 東芝 Battery electrode material, nonaqueous electrolyte battery, and battery pack
EP3127907A4 (en) * 2014-03-31 2018-04-04 Boston Biomedical, Inc. New tricyclic quinone derivative
US10464896B2 (en) 2015-06-11 2019-11-05 Basilea Pharmaceutica International AG Efflux-pump inhibitors and therapeutic uses thereof
AU2015101598A4 (en) * 2015-09-17 2015-12-03 Macau University Of Science And Technology Novel ros1 inhibitor and its use
EP3954372A1 (en) 2016-02-01 2022-02-16 Takeda Pharmaceutical Company Limited Cocrystal
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis
US11299469B2 (en) 2016-11-29 2022-04-12 Sumitomo Dainippon Pharma Oncology, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
JP7091201B2 (en) 2018-09-14 2022-06-27 株式会社東芝 Active materials, electrodes, rechargeable batteries, battery packs, and vehicles
RU2711968C1 (en) * 2018-11-22 2020-01-24 федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский национальный исследовательский политехнический университет" Analgesic agent
CN110172068A (en) * 2019-06-05 2019-08-27 河南龙湖生物技术有限公司 Benzothiazole compound with anti-tumor activity and its preparation method and application
US20230301950A1 (en) 2020-06-26 2023-09-28 Raqualia Pharma Inc. Method for selecting cancer patients for whom combination therapy with retinoid and cancer therapeutic agent is effective, and combination medicament with retinoid and cancer therapeutic agent
CN113292477B (en) * 2021-06-01 2023-06-02 四川大学 Method for synthesizing isoindole-1-ketone compound through iridium-catalyzed hydrocarbon activation reaction

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0587473A1 (en) * 1992-08-27 1994-03-16 Sanofi Condensed pyridine derivatives as inhibitors of the effects of free radicals
WO2004058772A1 (en) * 2002-12-26 2004-07-15 Daiichi Suntory Pharma Co.,Ltd. Dihydrothienoquinoline derivatives and cell adhesion inhibitors containing the same
WO2007022268A2 (en) * 2005-08-16 2007-02-22 Irm Llc Compounds and compositions as protein kinase inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3012684B2 (en) 1989-12-08 2000-02-28 大日本製薬株式会社 Thienoquinoline derivatives, thienonaphthyridine derivatives and their salts
WO1993013664A2 (en) 1992-01-11 1993-07-22 Schering Agrochemicals Limited Biheterocyclic fungicidal compounds
JP3223289B2 (en) 1992-10-22 2001-10-29 東洋アルミニウム株式会社 Meat cookware and meat cooking method
PL345906A1 (en) 1998-06-04 2002-01-14 Abbott Lab Cell adhesion-inhibiting antinflammatory compounds
WO2000075145A1 (en) 1999-06-03 2000-12-14 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
EP1465869B1 (en) 2001-12-21 2013-05-15 Exelixis Patent Company LLC Modulators of lxr
WO2004020599A2 (en) 2002-08-29 2004-03-11 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
US20050043346A1 (en) 2003-08-08 2005-02-24 Pharmacia Italia S.P.A. Pyridylpyrrole derivatives active as kinase inhibitors
EP1671962A1 (en) 2003-10-10 2006-06-21 Ono Pharmaceutical Co., Ltd. Novel fused heterocyclic compound and use thereof
JPWO2005063241A1 (en) 2003-12-26 2007-07-19 小野薬品工業株式会社 Preventive and / or therapeutic agent for mitochondrial benzodiazepine receptor mediated diseases
US20070299102A1 (en) 2004-04-08 2007-12-27 Topo Target A/S Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
AR056560A1 (en) * 2005-10-06 2007-10-10 Astrazeneca Ab PIRROLOPIRIDINONES AS MODULATORS CB1
JP5256047B2 (en) * 2006-01-27 2013-08-07 シャンハイ ヘンルイ ファーマシューティカル カンパニー リミテッド Pyrrolo [3,2-c] pyridin-4-one 2-indolinone protein kinase inhibitor
MX2008013204A (en) * 2006-04-14 2008-10-22 Novartis Ag Use of biarylcarboxamides in the treatment of hedgehog pathway-related disorders.
EP2527330A1 (en) * 2007-03-14 2012-11-28 Exelixis, Inc. Inhibitors of the hedgehog pathway
PE20090188A1 (en) * 2007-03-15 2009-03-20 Novartis Ag HETEROCYCLIC COMPOUNDS AS MODULATORS OF THE HEDGEHOG PATH
CN102015705B (en) 2008-02-26 2013-11-13 武田药品工业株式会社 Fused heterocyclic derivative and use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0587473A1 (en) * 1992-08-27 1994-03-16 Sanofi Condensed pyridine derivatives as inhibitors of the effects of free radicals
WO2004058772A1 (en) * 2002-12-26 2004-07-15 Daiichi Suntory Pharma Co.,Ltd. Dihydrothienoquinoline derivatives and cell adhesion inhibitors containing the same
WO2007022268A2 (en) * 2005-08-16 2007-02-22 Irm Llc Compounds and compositions as protein kinase inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113429422B (en) * 2021-07-26 2022-05-10 中国人民解放军军事科学院军事医学研究院 Thienoquinolone compound and preparation method and application thereof

Also Published As

Publication number Publication date
PE20091556A1 (en) 2009-11-03
JP2011513199A (en) 2011-04-28
CA2716773A1 (en) 2009-09-03
ECSP10010496A (en) 2010-10-30
TWI480282B (en) 2015-04-11
EP2247588B1 (en) 2016-04-13
EA020144B1 (en) 2014-09-30
AU2009217982A1 (en) 2009-09-03
JP2011098978A (en) 2011-05-19
CL2009000429A1 (en) 2009-09-25
GEP20125664B (en) 2012-10-10
AR070479A1 (en) 2010-04-07
IL207735A (en) 2014-12-31
NZ587719A (en) 2012-04-27
EA201070994A1 (en) 2011-04-29
AU2009217982B2 (en) 2013-04-11
IL207735A0 (en) 2010-12-30
CR11661A (en) 2010-10-11
JP4719317B2 (en) 2011-07-06
US20110003788A1 (en) 2011-01-06
DOP2010000260A (en) 2010-10-15
AU2009217982A2 (en) 2010-10-07
US8217176B2 (en) 2012-07-10
ZA201006063B (en) 2011-10-26
HK1150274A1 (en) 2011-11-18
BRPI0908417A2 (en) 2020-08-18
MA32164B1 (en) 2011-03-01
KR101569949B1 (en) 2015-11-18
JP5490030B2 (en) 2014-05-14
BRPI0908417B1 (en) 2022-01-11
US8399449B2 (en) 2013-03-19
CN102015705A (en) 2011-04-13
ES2586252T3 (en) 2016-10-13
KR20100137482A (en) 2010-12-30
TW200940548A (en) 2009-10-01
EP2247588A2 (en) 2010-11-10
MY150379A (en) 2013-12-31
CA2716773C (en) 2016-04-26
WO2009107850A2 (en) 2009-09-03
US20090227561A1 (en) 2009-09-10
MX2010009372A (en) 2010-09-22
CN102015705B (en) 2013-11-13
CO6321277A2 (en) 2011-09-20
JO3259B1 (en) 2018-09-16

Similar Documents

Publication Publication Date Title
WO2009107850A3 (en) Fused heterocyclic derivative and use thereof
WO2008156094A1 (en) Pyridazinone derivative and pde inhibitor containing the same as active ingredient
EP2017278A4 (en) Dihydropyrazolopyrimidinone derivative
EP1731523A4 (en) Thiazolopyrimidine derivative
WO2009019005A3 (en) Tricyclic bridged cyclopentanedione derivatives as herbicides
WO2008108380A3 (en) Pyrrole compounds
WO2006100082A3 (en) Substituted oxindol derivatives, drugs containing said derivatives and the use thereof
WO2008108378A3 (en) Bicyclic oxomorpholine derivative
WO2013010946A3 (en) Pesticidal methods using substituted 3-pyridyl thiazole compounds and derivatives for combating animal pests i
WO2011004162A3 (en) 1, 2, 4-thiazolidin-3-one derivatives and their use in the treatment of cancer
MX2014000452A (en) Azabenzimidazole derivative having ampk-activating activity.
MX2011008176A (en) 3, 3' -spiroindolinone derivatives as anticancer agents.
MY169179A (en) Novel piperidine compound or salt thereof
WO2012161071A8 (en) Nitrogenated heterocyclic compound and agricultural or horticultural fungicide
WO2009007115A8 (en) Tropane derivatives useful as pesticides
WO2008105526A1 (en) Macrocyclic compound
WO2008114812A1 (en) Jak inhibitor
WO2008126901A1 (en) Nitrogen-containing heterocyclic compound and pharmaceutical composition containing the same
MX2012002528A (en) Therapeutic agent for mood disorders.
WO2008156102A1 (en) Pyrazolone derivative and pde inhibitor containing the same as active ingredient
WO2008139845A8 (en) Novel amide derivative
MXPA06014551A (en) , ??-unsaturated esters and acids by stereoselective dehydration.
WO2008093838A1 (en) Pyridyl imidazolidine derivative having sulfamoyl group, and pharmaceutical use thereof
WO2013190123A8 (en) Pyrimidinone derivatives as antimalarial agents
MX2009014000A (en) Substituted aromatic heterocyclic compounds as fungicides.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980114811.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09714922

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 207735

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2010533355

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 12919413

Country of ref document: US

Ref document number: 2716773

Country of ref document: CA

Ref document number: 12010501938

Country of ref document: PH

Ref document number: MX/A/2010/009372

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 1001133

Country of ref document: KE

WWE Wipo information: entry into national phase

Ref document number: 2009714922

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 201011661

Country of ref document: CR

Ref document number: CR2010-011661

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 587719

Country of ref document: NZ

Ref document number: PI 2010004006

Country of ref document: MY

WWE Wipo information: entry into national phase

Ref document number: 2009217982

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 6453/DELNP/2010

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2009217982

Country of ref document: AU

Date of ref document: 20090225

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 10117653A

Country of ref document: CO

Ref document number: 10117653

Country of ref document: CO

Ref document number: DZP2010000586

Country of ref document: DZ

ENP Entry into the national phase

Ref document number: 20107021331

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 11952

Country of ref document: GE

Ref document number: 201070994

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: A201011405

Country of ref document: UA

ENP Entry into the national phase

Ref document number: PI0908417

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100824